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Summary
 
Certain major histocompatibility complex (MHC) class II haplotypes encode elements provid-
ing either susceptibility or dominant resistance to the development of spontaneous autoim-
mune diseases via mechanisms that remain undefined. Here we show that a pancreatic beta
cell–reactive, I-A
 
g7
 
–restricted, transgenic TCR that is highly diabetogenic in nonobese diabetic
mice (H-2
 
g7
 
) undergoes thymocyte negative selection in diabetes-resistant H-2
 
g7/b
 
, H-2
 
g7/k
 
,
H-2
 
g7/q
 
, and H-2
 
g7/nb1
 
 NOD mice by engaging antidiabetogenic MHC class II molecules on
thymic bone marrow–derived cells, independently of endogenous superantigens. Thymocyte
deletion is complete in the presence of I-A
 
b
 
, I-A
 
k
 
 
 
1
 
 I-E
 
k
 
 or I-A
 
nb1
 
 
 
1
 
 I-E
 
nb1
 
 molecules, partial
in the presence of I-A
 
q
 
 or I-A
 
k
 
 molecules alone, and absent in the presence of I-A
 
s
 
 molecules.
Mice that delete the transgenic TCR develop variable degrees of insulitis that correlate with
the extent of thymocyte deletion, but are invariably resistant to diabetes development. These
results provide an explanation as to how protective MHC class II genes carried on one haplo-
type can override the genetic susceptibility to an autoimmune disease provided by allelic MHC
class II genes carried on a second haplotype.
 
I
 
nsulin-dependent diabetes mellitus (IDDM),
 
1
 
 a proto-
type of organ-specific autoimmune diseases, results from
selective destruction of pancreatic beta cells by a T lym-
phocyte–dependent autoimmune process in genetically
predisposed individuals (1). Genetic susceptibility and/or
resistance to most autoimmune disorders, including IDDM,
is associated with highly polymorphic genes of the MHC
complex and, to a lesser extent, with polygenic modifiers
on other chromosomes (2).
Population and animal studies have suggested that the
MHC class II–linked susceptibility and resistance to IDDM
are inherited as dominant traits with incomplete penetrance
(2, 3). In humans, the MHC-associated IDDM susceptibil-
ity and resistance are predominantly, but not exclusively,
determined by polymorphisms at the human leukocyte an-
tigen (HLA) DQB1 locus. Alleles encoding DQ
 
b
 
 chains
with serine, alanine, or valine at position 57 provide sus-
ceptibility, whereas those encoding DQ
 
b
 
 chains with as-
partic acid at position 57 provide resistance with differing
degrees of dominance (1, 2). In mice, susceptibility and re-
sistance to spontaneous IDDM are also linked to the MHC
(H-2). The diabetes-prone nonobese diabetic (NOD) mouse,
which spontaneously develops a form of diabetes closely
resembling human IDDM, is homozygous for a unique
H-2 haplotype (H-2
 
g7
 
). This haplotype carries a nonpro-
ductive I-E
 
a
 
 gene and encodes an I-A
 
a
 
d
 
/I-A
 
b
 
g7
 
 het-
erodimer in which the histidine and aspartic acid found at
positions 56 and 57 in most murine I-A
 
b
 
 chains (the coun-
terpart of human DQ
 
b
 
 chains) are replaced by proline and
serine, respectively (4, 5). Studies of congenic NOD mice
expressing non-NOD MHC haplotypes, and of NOD
mice expressing I-E
 
a
 
d
 
, modified I-A
 
b
 
g7
 
, I-A
 
a
 
k
 
/I-A
 
b
 
k
 
, or
I-A
 
b
 
d
 
 transgenes, have demonstrated that MHC class II
molecules encoded by H-2 haplotypes derived from NOD
or IDDM-resistant mice play a direct role in providing ei-
ther susceptibility or resistance to spontaneous IDDM, re-
spectively (6–18).
The precise mechanisms through which MHC genes
provide autoimmune disease susceptibility and resistance,
however, remain mysterious. MHC molecules are cell-sur-
face receptors that present short fragments of self and for-
 
1
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eign proteins to T lymphocytes and play a pivotal role in
instructing T lymphocytes maturing in the thymus how to
discriminate between self- and nonself-antigens (19, 20).
Thymocytes bearing TCRs capable of recognizing self-pep-
tide–MHC complexes with high affinity/avidity die or are
rendered unresponsive to antigenic stimulation (21–27). In
contrast, thymocytes bearing TCRs capable of engaging
self-peptide–MHC complexes with intermediate affinity/
avidity survive and are exported to the peripheral lymphoid
organs as cells capable of recognizing foreign antigens bound
to self-MHC molecules (25–30). On the basis of some of
this knowledge, a number of authors hypothesized that
MHC molecules providing resistance to autoimmune dis-
eases, including IDDM, might do so by mediating the clonal
deletion or anergy of autoreactive T cells (8, 11, 31). Studies
in MHC-congenic NOD mice and in I-A-, I-E-, and
TCR-transgenic NOD mice, however, did not find evi-
dence of T cell tolerance induction, and suggested that the
diabetes resistance provided by protective MHC genes
likely involved the induction of immunoregulatory functions
(10, 13, 16, 18, 32, 33).
The studies presented here were initiated to test the hy-
pothesis that diabetes-resistant genetic backgrounds express
non-MHC–linked genetic elements other than endoge-
nous superantigens that are tolerogenic for diabetogenic T
cells. To that end, we followed the fate of an NOD islet-
derived, beta cell–specific, I-A
 
g7
 
–restricted transgenic TCR
in diabetes-prone NOD mice, and in diabetes-resistant F1
hybrid mice lacking endogenous superantigens binding to
the transgenic TCR. In NOD mice, T cells expressing the
transgenic TCR underwent positive thymic selection and
triggered a dramatic acceleration of the onset of IDDM. In
certain F1 hybrid strains, however, the same cells under-
went negative selection and the mice did not develop
IDDM. Contrary to what we expected, the thymocyte de-
letion and IDDM resistance observed in these mice coseg-
regated as a single locus trait with MHC haplotypes known
to provide dominant resistance to IDDM in MHC-trans-
genic and/or -congenic NOD mice (H-2
 
b
 
 and H-2
 
k
 
). Thy-
mocyte deletion in these mice was not mediated by endog-
enous superantigens, since it was absent in single-chain
TCR-
 
b
 
–transgenic H-2
 
g7/b
 
 and H-2
 
g7/k
 
 F1 mice. Studies
of bone marrow chimeras, I-A
 
b
 
b
 
–deficient H-2
 
g7/b
 
 mice
and I-A
 
k
 
–transgenic NOD mice demonstrated that the thy-
mocyte deletion and IDDM resistance of these mice re-
sulted from the ability of the transgenic TCR to engage I-A
 
b
 
,
I-A
 
k
 
, and possibly, I-E
 
k
 
 molecules on thymic bone mar-
row–derived cells. Additional experiments with H-2
 
g7/q
 
-
and H-2
 
g7/nb1
 
-congenic NOD mice revealed that this highly
pathogenic TCR was also deleted in the presence of I-A
 
q
 
and I-A/I-E
 
nb1
 
 molecules, which also provide dominant re-
sistance to autoimmune diabetes in non-TCR–transgenic
NOD mice. Our unexpected results provide an explanation
as to how protective MHC class II molecules may provide
resistance to spontaneous T cell–mediated autoimmune
disorders, i.e., by removing certain highly pathogenic au-
toreactive T cells.
 
Materials and Methods
 
Generation of TCR Transgenes.
 
The TCR-
 
a
 
 and -
 
b
 
 cDNAs
of NY4.1 were cloned by anchored PCR and multiple recombi-
nants sequenced as described (34). The cDNAs were then ampli-
fied by PCR using primers containing L-V and J-C intron se-
quences, the corresponding splice donor and acceptor sites and
convenient restriction sites, cloned into pBS-SK
 
1
 
 (Stratagene, La
Jolla, CA), and sequenced. Inserts with the expected sequences
were released from the vector by digestion with ClaI and NotI
(TCR-
 
b
 
) or XhoI and NotI (TCR-
 
a
 
). The 4.1-VDJ
 
b
 
 sequence
was subcloned into a TCR-
 
b
 
 shuttle vector carrying the endoge-
nous TCR-
 
b
 
 enhancer and 5
 
9
 
 regulatory sequences (3A9
 
b
 
; gift
from M. Davis, Stanford University, Stanford, CA). The 4.1-VJ
 
a
 
cDNA was subcloned into PRE53
 
a
 
 (from M. Davis). A 2.4-kb
ClaI–KpnI fragment from 4.1-VJ
 
a
 
/PRE53
 
a
 
, containing 5
 
9
 
 regu-
latory sequences and the 4.1-VJ
 
a
 
 sequence, was then coligated
into pBS-SK
 
1
 
 with a genomic 11.9-kb KpnI–NotI fragment
from AN6.2
 
a
 
 (provided by S. Hedrick, University of California
San Diego, San Diego, CA), containing the four C
 
a
 
 exons and
the downstream TCR-
 
a
 
 enhancer.
 
Production of Transgenic Mice.
 
After removing prokaryotic se-
quences by digestion with PvuI and SalI (TCR-
 
b
 
) or ClaI and
SacII (TCR-
 
a
 
), the constructs (21.5- and 14.5-kb, respectively)
were injected into fertilized (SJL 
 
3
 
 C57BL/6) F2 eggs (DNX,
Princeton, NJ). Offspring were screened for integration of the
transgenes by Southern blotting using VDJ
 
b
 
 and VJ
 
a
 
 cDNA
probes. Transgenic founder mice (4.1-AN6A3–TCR-
 
a
 
/
 
b
 
, 4.1-
AN6B3–TCR-
 
b
 
 and 4.1-AN6B7–TCR-
 
a
 
) were backcrossed
with NOD/Lt mice (I-A
 
g7
 
, I-E
 
2
 
; Jackson Laboratory, Bar Har-
bor, ME) for 3–5 generations to generate TCR-
 
a
 
/
 
b
 
–, TCR-
 
b
 
–,
and TCR-
 
a
 
–transgenic NOD mice. TCR-
 
a
 
–, TCR-
 
b
 
–, and
TCR-
 
a
 
/
 
b
 
–transgenic NOD mice (of the N5 backcross) were
crossed with SJL/J (S; I-A
 
s
 
, I-E
 
2
 
), C57BL/6 (B; I-A
 
b
 
, I-E
 
2
 
),
C58/J (C; I-A
 
k
 
, I-E
 
k
 
), NOD.H-2
 
g7/q
 
 (I-A
 
g7/q
 
, I-E
 
2
 
), or NOD.H-
2
 
g7/nb1
 
 (I-A
 
g7/nb1
 
, I-E
 
nb1
 
) mice (Jackson Laboratory), to generate
TCR-transgenic F1 mice or H-2 heterozygous TCR-transgenic
NOD mice. TCR-
 
a
 
/
 
b
 
–transgenic F1 (4.1-F1) mice were also
backcrossed with NOD, C57BL/6, or C58/J mice, to generate
H-2
 
g7
 
, H-2
 
g7/b
 
, H-2
 
g7/k
 
 4.1 mice with 75% NOD genotype, and
H-2
 
b
 
 or H-2
 
k
 
 4.1 mice with 75% C57BL/6 or C58/J genotypes,
respectively. I-Abb–deficient 4.1-(N 3 B) F1 mice were gener-
ated by crossing I-Abb2 C57BL-6 mice (Taconic, Germantown,
NY) with 4.1-NOD mice. b2 microglobulin (b2m)2 4.1-(N 3
B) F1 mice were obtained by breeding the b2m mutation of
b2m2 NOD/Lt mice (Jackson Laboratory) into 4.1-NOD mice,
to obtain b2m2 4.1-NOD mice, and then by crossing these mice
with  b2m2 C57BL/6 mice (Taconic). CD8-a2 H-2g7/b mice
were obtained by crossing CD8-a2 mice (I-Ab, I-E2) (gift from
T. Mak, University of Toronto, Toronto, Canada) with 4.1-
NOD mice, followed by crossing CD8-a2/1 4.1-H-2g7/b mice
with CD8-a2 H-2b mice. I-Ak–transgenic 4.1-NOD mice were
obtained by crossing I-Aak/I-Abk–transgenic NOD mice (from
G. Morahan and J.F.A.P. Miller, The Walter and Eliza Hall Insti-
tute, Victoria, Australia) with 4.1-NOD mice. Mice were screened
for inheritance of the transgenes, mutated alleles, and MHC hap-
lotypes by PCR of tail DNA (4.1a, 4.1b, b2m, I-Ag7, I-Ak) and/
or by flow cytometry (4.1b, CD8-a, I-Ab, I-As, Kd, Kk). All mice
were housed in a specific pathogen-free facility.
Antibodies and Flow Cytometry. Hybridomas secreting mAbs
H57-597 (anti–TCR-b), 53-6.7 (anti–CD8-a), B220 (anti–B
cells), and M1/70 (anti–Mac-1) were obtained from the Ameri-
can Type Culture Collection (ATCC, Rockville, MD). Anti–1061 Schmidt et al.
Lyt-2 (CD8-a)–PE (53-6.7), anti–L3T4–FITC (IM7), or anti–
L3T4–biotin (CD4; H129.19), anti–Vb11–FITC (RR3-15),
anti–H-2Kd–FITC (SF1-1.1), and anti–I-Abb–biotin (25-9-3)
were purchased from PharMingen (San Diego, CA). Purified
mouse anti–H-2Kk (11-4.1) was from Becton Dickinson (San
Jose, CA). Mouse IgG-absorbed FITC-conjugated goat anti–rat
IgG and FITC-conjugated goat anti–mouse IgG were from
CALTAG Labs. (South San Francisco, CA) and Becton Dickin-
son, respectively. Streptavidin-PerCP was from Becton Dickin-
son. Thymi, spleens, and islet-derived T cells were analyzed by
three-color flow cytometry using a FACScanÒ as described (35).
Cloning and Sequencing of TCR-a cDNAs. The TCR-a cDNA
molecules of splenic CD41 T cells were cloned and sequenced by
anchored PCR as described previously (35).
Preparation of CD81 T Cell–depleted Splenic and Islet-derived T
Cells. Spleens were disrupted into single cell suspensions and
red blood cells lysed in 0.87% ammonium chloride. Remaining
cells were washed with complete medium (CM: RPMI 1640 me-
dia containing 10% heat-inactivated fetal bovine serum [GIBCO
BRL, Gaithersburg, MD], 50 U/ml penicillin, 50 mg/ml strepto-
mycin [Flow Labs., McLean, VA], and 50 mM 2-ME [Sigma
Chemical Co., St. Louis, MO]) and then depleted of CD81 T
cells using anti-CD8 mAb (53-6.7)–coated magnetic beads as de-
scribed (35). Islet-infiltrating CD41 T cells were isolated from
acutely diabetic 4.1-NOD mice essentially as described previously
(35), analyzed by flow cytometry, depleted of CD81 T cells by
negative selection with anti-CD8 mAb-coated immunobeads,
expanded in rIL-2–containing CM for 1–2 wk, and used for in
vitro and in vivo studies.
Proliferation Assays. Pancreatic islets from 5–8-wk-old non-
transgenic male NOD mice were dispersed into single cells by in-
cubation in Ca21- and Mg21-free PBS containing 0.125% trypsin
and 3 mM EGTA at 378C for 3 min. 2 3 104 splenic or islet-
derived CD41 cells were incubated, in triplicate, with g-irradi-
ated (3,000 rad) islet cells (3–100 3 103/well) and unfractionated
NOD splenocytes (105/well), as a source of antigen and APCs,
respectively, in 96-well round-bottomed tissue culture plates for
3 d at 378C in 5% CO2 in rIL-2–free CM. Cultures were pulsed
with 1 mCi of [3H]thymidine during the last 18 h of culture and
harvested. The incorporated thymidine was measured by scintilla-
tion counting. Specific proliferation was calculated by substract-
ing background proliferation (cpm of cultures containing islet
cells plus APCs alone and cpm of cultures of T cells alone) from
islet cell–induced proliferation (cpm of cultures containing T
cells, APCs, and islet cells).
For anti–TCR-b stimulation, 96-well flat-bottomed plates
were precoated overnight at 48C with serial dilutions of purified
anti–TCR-b mAb (H57-597; 0.3–10 mg/ml) in 50 mM Tris-
HCl, 150 mM NaCl (pH 9.5), and washed three times in CM.
CD41 T cells (2 3 104) were added to each well in triplicate, in-
cubated for 48 h, pulsed with [3H]thymidine for 18 h, harvested,
and analyzed by scintillation counting.
Histology and Immunopathology. The body-tail of each pan-
creas was divided into two pieces. One piece was fixed in forma-
lin, embedded in paraffin, sectioned at 4.5 mM, and stained with
hematoxylin and eosin. The degree of insulitis was evaluated by
scoring 15–30 islets/mouse in a blinded fashion using the follow-
ing criteria: 0, normal islet; 1, peri-insulitis; 2, mononuclear cell
infiltration in ,25% of the islet; 3, mononuclear cell infiltration
in 25–50% of the islet; 4, .50% of the islet infiltrated. A second
piece of tissue was snap frozen, immersed in OCT, sectioned at
6–7 mM, and stored at 2808C for immunopathology. Sections
were fixed in cold acetone for 10 min and stained with anti-CD4
(GK1.5), anti-CD8 (53-6.7), anti–Mac-1, and anti-B220 mAbs,
followed by anti–rat IgG-FITC, or with anti-rat IgG-FITC
alone, as described (35).
Adoptive T cell Transfer. CD81 T cell–depleted islet-derived
CD41 T cells from diabetic 4.1-NOD mice (5 3 106 cells/
mouse) were transfused into the tail veins of scid-NOD/Lt (Jack-
son Laboratory) in 200 ml of PBS, pH 7.2. Transfused mice were
followed for development of IDDM by monitoring blood glu-
cose levels with Glucostix and a glucometer (Miles Canada, Eto-
bicoke, Ontario). Mice were killed at IDDM onset for flow cy-
tometry and immunopathological studies.
Bone Marrow Chimeras. Bone marrow chimeras were gener-
ated following standard protocols (36). In brief, bone marrow
suspensions (5–10 3 106 cells) from donor mice (transgenic
NOD or [N 3 B] F1 mice) were injected into the tail vein of re-
cipient mice (nontransgenic NOD, [N 3 B] F1 or [N 3 S] F1
mice) treated with two doses of 500 rads 3 h apart from a 137Cs
source (Gammacell; Atomic Energy of Canada, Ottawa, On-
tario). Chimeric mice were killed 5–6 wk after bone marrow
transplantation.
Statistical Analyses. Statistical analyses were performed using
Mann-Whitney U and x2 tests.
Results
Generation of Beta Cell–specific, I-Ag7–restricted TCR-a/b–
transgenic NOD Mice. A CD41 T cell clone (NY4.1) that
was derived from pancreatic islets of a diabetic NOD
mouse and that recognized a putative beta cell autoantigen
in the context of I-Ag7 (37) was chosen as donor of the
TCR transgenes. This T cell clone transcribed one func-
tional TCR-b rearrangement, carrying Vb11 and Jb2.4 se-
quences and one functional TCR-a rearrangement, carry-
ing a novel Va gene (Vax4.1) and the Ja33 element (These
sequence data are available from EMBL/GenBank/DDBJ
under accession numbers U80816 and U80817). These TCR
rearrangements were subcloned into genomic TCR-b and
-a shuttle vectors carrying endogenous TCR enhancers and
59-regulatory sequences. The resulting genomic constructs
were then used to produce transgenic mice. Founders express-
ing the transgenes (4.1-AN63A–TCR-a/b, 4.1-AN6B3–
TCR-b, and 4.1-AN6B7–TCRa) were crossed with NOD
mice for several generations to generate 4.1–TCR-a/b-,
4.1–TCR-b–, and 4.1–TCR-a–transgenic NOD mice, re-
spectively.
Expression of the 4.1-TCR in 4.1–TCR-a/b–transgenic
NOD (4.1-NOD) Mice. Three-color cytofluorometric stud-
ies showed that .90% CD41CD82 thymocytes (Fig. 1 A)
and splenic CD41 T cells (Fig. 1 B) from 4.1-NOD mice
expressed Vb111 TCRs, compared to z6% of the
CD41CD82 thymocytes and splenic CD41 T cells from
nontransgenic littermates, thus indicating TCR-b trans-
gene expression. Although we do not have a transgenic
TCR-a chain-specific antibody and thus cannot directly
quantitate TCR-a transgene expression, five different lines
of evidence suggest that the transgenic TCR-a chain is ex-
pressed on a sizeable fraction of thymocytes and peripheral
T cells of 4.1-NOD mice. First, CD41CD81 thymocytes
from 4.1-NOD mice expressed higher levels of total TCR-1062 T Cell Tolerance versus the MHC-linked Resistance to Diabetes
Figure 1. Expression of the TCR-a/b transgenes in 4.1-NOD mice.
(A and B) CD4, CD8, and Vb11 profiles of thymocytes (A) and splenic
cells (B) from transgenic and nontransgenic mice. (Top) CD4 versus CD8
dot plots of cell suspensions stained with anti–CD8–PE, anti–Vb11–
FITC, and anti–CD4–biotin plus Streptavidin-PerCP. (Bottom) Vb11 flu-
orescence histograms of each T cell subset after electronic gating. Num-
bers indicate the average percentage of cells (top) or the average number
of Vb111 cells (bottom) in each subset. Data correspond to 6–10 3–5-wk-
old mice/group. DP, double-positive cells; DN, double-negative cells.
(C) In vitro proliferation of splenic CD41 T cells in response to islet cells.
Cultures of 2 3 104 splenic CD41 T cells from TCR-a/b–transgenic,
TCR-b–transgenic, and nontransgenic NOD mice were incubated with
g-irradiated NOD islet cells and splenocytes (105/well) for 3 d, pulsed
with [3H]thymidine, and harvested. Bars show the standard error of the
means.1063 Schmidt et al.
a/b (as determined by staining with an anti-Cb mAb) than
CD41CD81 thymocytes from TCR-b–transgenic NOD
mice (mean fluorescence intensities: 59 6 12 versus 31 6
3, respectively; P ,0.001), suggesting early TCR-a chain
expression (23, 38, 39). Second, thymocyte development
in 4.1-NOD mice, but not TCR-b–transgenic NOD
mice, was skewed towards the CD41CD82 subset (Fig. 1
A), compatible with TCR-a transgene-dependent positive
selection of 4.1-CD41 thymocytes. Third, skewing of thy-
mocytes into the CD41CD82 subset occurred in trans-
genic mice expressing the selecting I-Ag7 molecule, but not
in transgenic mice expressing only nonselecting I-A mole-
cules (i.e., I-As, see below), as seen with other MHC class
II–restricted TCR-a/b–transgenic models (38, 40). Fourth,
37 out of 37 4.1-NOD TCR-a cDNA sequences, gener-
ated from splenic CD41 T cell–derived RNA by anchored
PCR, were TCR-a transgene–derived. Finally, splenic
CD41 T cells from 4.1-NOD, but not TCR-b–transgenic
or nontransgenic, NOD mice proliferated in a dose-depen-
dent manner in response to irradiated NOD islet cells (Fig.
1 C). The islet cell–induced proliferation of 4.1- and con-
trol CD41 T cells was quite variable between experiments,
perhaps due to variability in the quality of the islet cell
preparations; however, the differences within individual
experiments were reproducible. Taken together, these re-
sults provide strong evidence that in 4.1-NOD mice, the
4.1-TCR specificity is expressed appropriately, and that, in
the presence of the selecting I-Ag7 molecule, 4.1–TCR-a/b
transgene expression fosters the positive selection of beta
cell–reactive CD41 T cells.
Early Onset of IDDM in 4.1-NOD Mice. To determine
whether  positive selection of the beta cell–specific TCR in
4.1-NOD mice had any pathogenic significance, we fol-
lowed 4.1-NOD mice of the N3–N5 backcrosses of the
founder mouse onto the NOD background, and nontrans-
genic NOD mice for development of IDDM. As shown in
Fig. 2 A, 4.1-NOD mice developed IDDM much earlier
than nontransgenic NOD mice (IDDM onset at 43.6 6 13
versus 119 6 26 d in females, and at 56 6 27 versus 157 6
28 d in males; P ,0.0001) (Fig. 2 A). In males, transgene
expression also increased the incidence of IDDM (73.3
versus 45.7%; P ,0.05). The kinetics of disease penetrance
in the transgenic and nontransgenic populations were,
however, remarkably similar (Fig. 2 A). Disease accelera-
tion in 4.1-NOD mice required coexpression of the TCR-a
and -b transgenes, since the few 4.1–TCR-b–NOD mice
that became diabetic (3/7, 43%) did so significantly later
than 4.1-NOD mice (103 6 20 versus 46 6 19 d; P
,0.01). These results contrast with those obtained with the
only other existing beta cell–specific TCR-transgenic
NOD mouse model (32), which, when housed under spe-
cific pathogen-free conditions, develops IDDM less fre-
quently and significantly later (10–15% at 6 mo) than 4.1-
NOD mice (41). Taken together, our results indicate that
the 4.1–TCR-a/b is highly diabetogenic in the NOD
background, and suggest that the events that trigger accel-
erated diabetogenesis in 4.1-NOD mice are similar to those
that trigger IDDM in nontransgenic NOD mice.
To investigate the mechanisms underlying disease accel-
eration in 4.1-NOD mice, we then followed the progres-
sion of insulitis in prediabetic and diabetic mice. Histo-
pathological studies of pancreata from 3- and 6-wk-old
prediabetic 4.1-NOD mice showed that acceleration of di-
abetes in these mice was a result of faster progression, but
not earlier onset, of islet inflammation (Fig. 2 B). As ex-
pected, the insulitis lesions of diabetic 4.1-NOD mice con-
tained more CD41 and fewer CD81 T cells (but similar
numbers of B cells and macrophages [not shown]), than those
of diabetic nontransgenic NOD mice (Fig. 2 C). Islet-
derived CD41 T cells from 4.1-NOD mice expressed high
levels of the transgene-encoded Vb111 chain (Fig. 2 D), pro-
liferated in response to NOD islet cells in vitro (Fig. 2 E),
and transcribed messenger RNA for IL-2 and IFN-g, but
not IL-4 (data not shown). These data indicate that these
cells were transgenic, beta cell reactive, and of the Th1
type, as expected. Moreover, purified islet-derived CD41
T cells from three different diabetic 4.1-NOD mice were
able to transfer IDDM into three different scid-NOD mice
shortly after transfusion (36 6 12 d) in the absence of
CD81 T cells in the inflamed islets (Fig. 2 F). We thus
conclude that expression of the 4.1-TCR in the NOD
background promotes the selection of highly diabetogenic
CD41 Th1 cells and their accelerated recruitment into
pancreatic islets, leading to massive beta cell destruction
and IDDM within the first few weeks of life.
Thymocyte Deletion, and Insulitis and IDDM Resistance in
4.1-F1 Hybrid Mice. The exquisite pathogenicity of the
4.1-TCR provided us with a powerful tool with which to
test our initial hypothesis that diabetes-resistant back-
grounds encode non-MHC–linked elements other than
endogenous mouse mammary tumor virus superantigens
(vSAgs) that are tolerogenic for diabetogenic T cells. To
investigate this, we crossed 4.1-NOD mice (H-2g7) with
SJL/J (H-2s), C57BL/6 (H-2b), and C58/J mice (H-2k); F1
mice resulting from crosses of nontransgenic NOD mice
with these strains express the diabetogenic I-Ag7 molecule,
but are diabetes-resistant, and do not delete Vb111 T cells
(42). The lack of vSAg-mediated deletion of Vb111 or
Vax4.11 cells in these backgrounds was confirmed by the
fact that the thymocyte profiles of single-chain TCR-b– or
TCR-a–transgenic F1 mice and those of TCR-b– or
TCR-a–transgenic NOD mice, respectively, were indis-
tinguishable; as shown in Fig. 3, the percentages of thymic
and splenic CD41CD82Vb111 cells in TCR-b–transgenic
(Fig. 3 A) or nontransgenic F1 mice (Fig. 3 B) were virtu-
ally identical to (if not greater than) those seen in TCR-
b–transgenic or nontransgenic NOD mice, respectively.
The flow cytometric profiles of thymocytes (Fig. 4 A)
and splenocytes (Fig. 4 B) from 4.1-(N 3 S) F1 mice (n 5
8) were comparable to those seen in 4.1-NOD mice (Fig.
1), indicating that the 4.1-TCR specificity also undergoes
positive selection in H-2g7/s mice. In contrast, all 4.1-(N 3
B) F1 mice (n 5 22) and most 4.1-(N 3 C) F1 mice (n 5
16/19) had only one-third to one-half the number of thy-
mocytes seen in 4.1-NOD mice (and 4.1-[N 3 S] F1 mice),
and displayed flow cytometric profiles of thymocytes and1064 T Cell Tolerance versus the MHC-linked Resistance to Diabetes
Figure 2. 4.1-TCR-a/b–transgene expression and diabetogenesis. (A) Cumulative incidence of IDDM in female (25 transgenic and 114 nontransgenic)
and male (15 transgenic and 59 nontransgenic) NOD mice. (B) Progression of insulitis in transgenic and nontransgenic NOD mice. Hematoxylin–eosin
stained pancreatic sections of 3- and 6-wk-old mice (4–13 mice/age group) were scored for the degree of insulitis as described in Materials and Methods (41065 Schmidt et al.
splenocytes compatible with negative selection of the 4.1-
TCR, as compared with other TCR-a/b–transgenic mod-
els (23, 24, 39, 43) (Fig. 4). When compared to 4.1-NOD
mice, 4.1-(N 3 B) F1 and 4.1-(N 3 C) F1 mice (also re-
ferred to as “deleting”) displayed a significant reduction in
the percentage of CD41CD82 thymocytes, a reduction in
the percentage of CD41CD82 thymocytes expressing the
transgene-encoded Vb11 element, and an increase in the per-
centage of CD42CD82 thymocytes (Fig. 4 A). In the spleen,
4.1-NOD mice had significantly more CD41 T cells and
more CD41 T cells expressing Vb111 TCRs than deleting
mice (Fig. 4 B). The few Vb111CD41 T cells that matured
in deleting mice expressed half as many transgenic TCR-b
chains on the cell surface (but comparable numbers of total
TCR-a/b complexes) as Vb111CD41 T cells of 4.1-
NOD mice, both in the thymus and in the spleen (P
,0.003; data not shown), suggesting that in deleting mice
these cells were selected on endogenous TCR chains that
had bypassed allelic exclusion, as seen in other models (23,
24, 39, 43).
Proliferation assays using splenic CD41 T cells as re-
sponders and irradiated NOD islet cells and splenocytes as
antigen and APCs, respectively, revealed the absence of
beta cell–reactive CD41 T cells in the periphery of delet-
ing, but not nondeleting, 4.1-F1 mice (Fig. 5 A). Lack of
proliferation in these assays was the result of deletion,
rather than anergy, since peripheral CD41 T cells from de-
leting and nondeleting 4.1-F1 mice proliferated similarly in
response to plate bound anti–TCR-a/b mAb (Fig. 5 B).
The absence of diabetogenic 4.1 T cells in the peripheral
lymphoid organs of deleting mice was confirmed by the
observation that, like their nontransgenic littermates, 4.1-F1
hybrid mice developed neither diabetes nor insulitis (Table 1).
Taken together, these data indicate that: (a) C57BL/6
and C58/J mice carry genes encoding elements capable of
mediating the deletion of the diabetogenic 4.1-TCR; (b)
the deleting element(s) expressed by these strains has com-
plete or incomplete penetrance, respectively; and (c) these
elements are not encoded by vSAgs and target T cells coex-
pressing both chains of the diabetogenic TCR.
Thymocyte Deletion and Resistance to Insulitis and IDDM
Cosegregate with H-2b and H-2k. Previous studies have sug-
gested  that the IDDM resistance provided by certain non-
NOD MHC class II genes, including I-Ab and I-Ak, in-
volves the induction of immunoregulatory functions rather
than the deletion or anergy of autoreactive T cells (10, 16,
18, 32, 33, 44). Accordingly, we hypothesized that thy-
mocyte deletion in 4.1-F1 hybrid mice would be mediated
by elements encoded by non-MHC–linked genes. To test
this hypothesis, we backcrossed 4.1-F1 mice with NOD
mice and investigated whether thymocyte deletion and
IDDM resistance in the transgenic offspring (4.1-F2 mice)
segregated away from the H-2 haplotypes of the deleting
backgrounds (H-2b and H-2k). All 4.1-F2 mice were killed
at IDDM onset, or at 10 wk if nondiabetic, to determine:
(a) their H-2 phenotypes, (b) the occurrence of thymocyte
deletion; and (c) the degree of insulitis. Unexpectedly, we
found that deletion of 4.1 thymocytes segregated as a sin-
gle-locus trait linked to the MHC; it occurred in H-2g7/b
(16/16 mice, 100%) or H-2g7/k mice (9/15 mice, 60%; in-
cidence of deletion comparable to that seen in [N 3 C] F1
mice), but never in H-2g7/g7 mice (0/24 mice, 0%) (Table
2). Like deleting 4.1-F1 mice, deleting 4.1-F2 mice did not
harbor detectable beta cell–reactive CD41 T cells in the
spleen (data not shown). Furthermore, deleting H-2g7/b or
H-2g7/k 4.1-F2 mice developed neither IDDM nor insuli-
tis, whereas H-2g7/g7 4.1-F2 mice developed moderate to
severe insulitis (100%) and diabetes (z50%) within 10 wk
(Table 2). These data thus indicate that the deleting ele-
ments of C57BL/6 and C58/J mice are encoded by genes
tightly linked to their H-2b and H-2k complexes, and dem-
onstrate that insulitis and diabetes resistance in 4.1-F2 mice
is the maximum score). Bars show the standard deviation of the means. *P ,0.0001 (x2). (C) Phenotype of islet-infiltrating T cells in nontransgenic and
transgenic NOD mice. Pancreas sections were stained with anti-CD8 (53.6-7) or anti-CD4 (GK1.5) mAbs and FITC-labeled anti–rat IgG. Original magni-
fication: 200. (D) Flow cytometric profile of islet-derived T cells from diabetic 4.1-NOD mice. (E) Islet cell reactivity of islet-derived CD41 T cells from
4.1-NOD mice. See legend to Fig. 1 C for details. (F) Phenotype of islet-infiltrating T cells in a diabetic scid-NOD mice that had been transfused with
CD81 T cell–depleted CD41 T cells (5 3 106) derived from islets of a diabetic 4.1-NOD mouse.
Figure 3. Absence of deletion
of Vb111CD41 T cells in
TCRb–transgenic (A) and non-
transgenic (B) F1 hybrid mice.
Data correspond to average val-
ues from 3–6 mice/group. T,
thymocytes; S, splenocytes. *P
,0.02.1066 T Cell Tolerance versus the MHC-linked Resistance to Diabetes
carrying these haplotypes results from deletion of diabeto-
genic thymocytes.
I-Ab and I-Ak Molecules as Triggers of 4.1 Thymocyte Dele-
tion. The data presented above suggested that the deletion
of transgenic thymocytes and the IDDM resistance ob-
served in 4.1-F1 and -F2 mice might be mediated by
MHC class I and/or class II molecules encoded by the pro-
tective H-2 haplotypes. To determine whether 4.1 thy-
mocyte deletion required the engagement of MHC class I
molecules, we followed the maturation of 4.1 thymocytes
in CD8-a- or b2m-deficient 4.1-(N 3 B) F1 mice (H-2g7/b),
which either do not express the MHC class I-binding CD8
Figure 4. CD4, CD8, and Vb11 profiles of thymocytes (A) and splenic cells (B) from transgenic F1 hybrid mice. See legend to Fig. 1 for details. Data
shown are average values of 7–29 mice/group. In the text, transgenic NOD are referred to as 4.1-NOD; (NOD 3 SJL) F1-TG as 4.1-(N 3 S) F1;
(NOD 3 B6) F1-TG as 4.1-(N 3 B) F1; and (NOD 3 C58) F1-TG as 4.1-(N 3 C) F1. When compared to 4.1-NOD mice, 4.1-(N 3 B) F1 and 4.1-
(N 3 C) F1 mice had fewer CD41CD82 thymocytes (P ,0.0002), fewer Vb111CD41CD82 thymocytes (P ,0.0002), and more CD42CD82 thy-
mocytes (P ,0.0002) (A). In the spleen (B), 4.1-NOD mice had more CD41 T cells (P ,0.0001) and more Vb111 CD41 T cells (P ,0.002) than 4.1-
(N 3 B) F1 and 4.1-(N 3 C) F1 mice. All comparisons were done using the Mann-Whitney U test.1067 Schmidt et al.
coreceptor on thymocytes, or lack MHC class I molecules,
respectively. These mice deleted transgenic thymocytes as
efficiently as wild-type 4.1-F1 mice (data not shown), thus
indicating that deletion of transgenic thymocytes was not
mediated by MHC class I molecules.
Since H-2g7/b mice do not express I-E molecules, we
reasoned that deletion in these mice might be mediated by
I-Ab. To test this notion, we followed the development of
4.1 thymocytes in I-Abb–deficient 4.1-(N 3 B) F1 mice;
except for the I-Abb mutation, I-Abb–deficient 4.1-(N 3
B) F1 and 4.1-(N 3 B) F1 mice are genetically identical.
Selective abrogation of I-Abb expression in 4.1-(N 3 B)
F1 mice restored, at least in part, the positive selection of
the transgenic TCR, as evidenced by (a) significant in-
creases in the percentage of Vb111 thymocytes (Table 3),
(b) significant increases in the ratio of CD41CD82 to
CD42CD82 T cells in the thymus and in the ratio of
CD41 to CD81 T cells in the spleen (Table 3), (c) the reap-
pearance of beta cell–reactive CD41 T cells in the spleen
(Fig. 6, left), and (d) the reemergence of insulitis (Table 3).
The overall positive selection of the 4.1-TCR in I-Abb–
deficient 4.1-(N 3 B) F1 mice, however, was less efficient
than in 4.1-NOD mice; I-Abb–deficient 4.1-(N 3 B) F1
mice had more CD42CD82 thymocytes than, and half the
splenic CD41 T cells of, age-matched (3–5-wk-old) 4.1-
NOD mice (Table 3). Furthermore, the peripheral CD41
T cells of I-Abb–deficient 4.1-(N 3 B) F1 mice prolifer-
ated less efficiently in response to NOD islet cells than the
peripheral CD41 T cells of 4.1-NOD mice (Fig. 6, left). Fi-
nally, the insulitis lesions of I-Abb–deficient 4.1-(N 3 B)
F1 mice were milder than those seen in 4.1-NOD mice
and did not lead to IDDM in any of the 15 mice that were
followed (Table 3). Therefore, the I-Abb gene is not the
only protective element present in (N 3 B) F1 mice, but
its expression is sufficient in and of itself to induce deletion
of 4.1 thymocytes.
To investigate whether the H-2k–dependent deletion of
thymocytes in 4.1-(N 3 C) F1 mice was also I-A medi-
ated, we crossed 4.1-NOD mice with I-Aak/I-Abk (I-Ak)-
transgenic NOD mice, to generate 4.1/I-Ak–NOD mice.
Except for the presence of the I-Ak transgenes in 4.1/I-Ak–
NOD mice, 4.1-NOD and 4.1/I-Ak–NOD mice have vir-
tually identical genetic backgrounds. We found that 4.1-
NOD mice had significantly more thymocytes (data not
shown) and greater ratios of CD41CD82 to CD42CD82
thymocytes and of CD41 to CD81 splenocytes than 4.1/
Figure 5. In vitro prolifera-
tion of naive splenic CD41 T
cells from F1 hybrid mice to islet
cells (A) and immobilized anti–
TCR-b mAb (B). Proliferation
assays in A were done as in Fig. 1
C. For anti–TCR-b–induced
proliferation (B), CD41 T cells
(2 3 104) were added in tripli-
cate to wells precoated with se-
rial dilutions of anti–TCR-b
mAb (H57-597). Bars show the
standard error of the means.
Table 1. Insulitis and Diabetes in NOD versus F1 Hybrid Mice*
n IDDMi Age at Onset¶ Insulitis Score (n)¶
dx   6   SD
NOD-TG 40 30/40a 48 6 20g 3.74 6 0.15‡i(4)
NOD–non-TG 173 123/173b 138 6 27h 1.59 6 0.58‡j(13)
(NOD 3 B6) F1-TG 10 0/10c – 0.42 6 0.81§k(10)
(NOD 3 B6) F1–non-TG 12 0/12d –0 §l(12)
(NOD 3 C58) F1-TG 15 0/15e – 0.42 6 0.70§m(15)
(NOD 3 C58) F1–non-TG 4 0/4f –0 §n(4)
*Groups include both males and females.
‡6-wk-old mice; §15-wk-old mice.
Insulitis (15–30 islets/mouse) was scored as described in Materials and Methods.
x 6 SD, mean 6 standard deviation; TG, transgenic.
a versus c,e, b versus d,f, g versus h, j versus l: P ,0.0001; i versus j: P ,0.003; i versus k: P ,0.0005; i versus m, j versus n: P ,0.0032.
Data was compared by x2 (i) and Mann-Whitney U test(¶).1068 T Cell Tolerance versus the MHC-linked Resistance to Diabetes
I-Ak–NOD mice (Table 3), results compatible with dele-
tion of 4.1 thymocytes in 4.1/I-Ak–NOD mice. This dele-
tion, however, was incomplete; unlike the splenic CD41 T
cells of deleting H-2g7/k 4.1-F2 mice, the few CD41 T cells
that matured in 4.1/I-Ak–NOD mice expressed high levels
of the transgenic TCR-b chain, and these cells proliferated
in response to beta cells in vitro (Tables 2 and 3; and Fig. 6,
middle). Furthermore, unlike deleting H-2g7/k 4.1-F2 mice,
4.1/I-Ak–NOD mice developed moderate insulitis, sug-
gesting that these cells were also responsive to antigen stim-
ulation in vivo (Table 3). The insulitis lesions of these
mice, however, were less severe than those of 4.1-NOD
mice, and did not lead to diabetes in any of the nine mice
that were followed (Table 3). It appears, then, that (a) dele-
tion of thymocytes in H-2g7/k 4.1 mice is triggered, at least
in part, by I-Ak molecules, and (b) in addition to causing
partial deletion of 4.1 thymocytes, I-Ak molecules may
somehow abrogate the diabetogenic potential of the 4.1 T
cells that escape deletion.
Thymocyte Deletion in 4.1-NOD.H-2g7/q and 4.1-
NOD.H-2g7/nb1 Mice. We next asked whether the 4.1-
TCR could engage additional antidiabetogenic MHC class
II molecules during thymocyte development. We therefore
crossed 4.1-NOD mice with NOD mice congenic for H-2q
or H-2nb1 haplotypes, which provide dominant resistance
to diabetes in nontransgenic NOD.H-2g7/q or nb1 mice (7,
15), and followed the fate of the 4.1-TCR in the TCR-
transgenic offspring. As shown in Table 3 and Fig. 6 (right)
4.1-NOD.H-2g7/q and 4.1-NOD.H-2g7/nb1 mice had phe-
notypes compatible with partial or complete deletion of the
4.1-TCR, respectively. When compared to 4.1-NOD
mice, 4.1-NOD.H-2g7/q mice had twofold fewer thy-
mocytes (data not shown), increased percentages of CD42
CD82 thymocytes, and reduced percentages of thymic and
splenic CD41CD82 T cells (Table 3). The splenic CD41
T cells of these mice proliferated in response to NOD islet
cells in vitro, but did so less efficiently than those of 4.1-
NOD mice (Fig. 6, right). Furthermore, these mice only
developed very mild periinsulitis and never became dia-
betic (Table 3). In contrast, thymocyte deletion in 4.1-
NOD.H-2g7/nb1 mice was complete; these mice had a
three- to fourfold reduction in the absolute number of thy-
mocytes (data not shown), dramatically increased percent-
ages of CD42CD82 thymocytes, and reduced percentages
of thymic and splenic Vb111CD41CD82 T cells (Table
3). These mice did not contain detectable beta cell–reactive
CD41 T cells in the spleen (Fig. 6, right) and developed
neither diabetes nor insulitis (Table 3). Thymocyte deletion
in these mice was not mediated by putative NOD vSAgs (i.e.,
mouse mammary tumor virus superantigen 17) binding to
Vb11 and H-2q or H-2nb1 MHC class II molecules, since
the spleens of nontransgenic NOD. H-2g7/q and NOD.H-
Table 2. Cosegregation of Thymocyte Deletion and Resistance to Insulitis and IDDM with H-2b and H-2k Haplotypes in 4.1-transgenic Mice*
H-2
Deleting
status
Thymocyte profile
Age 
at onset
Insulitis 
score ‡,i (n) n
CD41CD82 
(Vb111) CD41CD81 CD42CD82 CD42CD81 IDDM
%, x 6 SDi n§ dx   6  SD
(NOD 3 B6) F1
3 NOD H-2g7 15 2 31 6 7a 44 6 12 22 6 7f 3 6 1 7/15k 53 6 17 2.4 6 1.4 (8)p
(92 6 2)a
H-2g7/b 16 1 15 6 3b 49 6 12 33 6 10g 3 6 1 0/16l – 0.4 6 0.6 (16)q
(66 6 5)b
(NOD 3 C58) F1
3 NOD H-2g7 9 2 35 6 5c 43 6 7 19 6 4h 3 6 2 5/9m 47 6 16 3.4 6 0.7 (4)r
(93 6 1)c
H-2g7/k 6 2 35 6 4d 45 6 8 16 6 6i 4 6 2 0/6n – 1.7 6 1.2(6)s
(89 6 9)d
H-2g7/k 9 1 17 6 3e 45 6 6 33 6 6j 4 6 3 0/9o – 0.2 6 0.2 (8)t
(58 6 9)e
*All mice were killed at IDDM onset or at 10 wk if nondiabetic. Flow cytometry was done as described in the legend to Fig. 1.
‡Nondiabetic mice only.
Groups of mice include both male and female mice (z 50% each). No differences in the incidence of IDDM nor in the degree of insulitis were
noted between female and male mice within groups. Insulitis (15–30 islets/mouse) was scored as described in Materials and Methods.
a versus b,c versus e,d versus e,f versus g,h versus j,m versus j: P ,0.0002; k versus l: P ,0.0001; m versus n, m versus o, s versus t: P ,0.002; p versus q:
P ,0.0006; r versus s: P ,0.0007; r versus t: P ,0.01 (compared by x2[§] and Mann-Whitney U test [i]).1069 Schmidt et al.
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2g7/nb1 littermates harbored more Vb111CD41 T cells than
nontransgenic NOD mice (20 6 7 and 12 6 2% versus 6
6 1%, P ,0.008 and P ,0.04, respectively).
Thymocyte Deletion in H-2 Heterozygous 4.1 Mice Is Not
Restricted by I-Ag7. To elucidate whether in vivo deletion
of 4.1 thymocytes was “restricted” by I-Ag7 molecules, we
next studied thymocyte maturation in 4.1 mice homozy-
gous for either nonselecting/nondeleting (H-2s) or deleting
(H-2b or H-2k) MHC haplotypes. As expected, 4.1 thy-
mocytes underwent neither positive nor negative selection
in H-2s 4.1 mice; these mice had significantly fewer
CD41CD82 thymocytes (but not more CD42CD82 thy-
mocytes) than H-2g7/s 4.1 mice (compare Fig. 4, left and 7,
left; P ,0.005). In contrast, the thymocyte profiles of H-2b
and H-2k 4.1 mice were compatible with deletion; these
mice had fewer thymocytes and greater percentages of
CD42CD82 thymocytes than H-2s 4.1 mice (Fig. 7, middle
and right). Therefore, unlike the positive selection of 4.1 T
cells in selecting (I-Ag71) mice, the I-Ab– and I-Ak–medi-
ated deletion of 4.1 thymocytes in 4.1-F1 mice is not I-Ag7–
restricted.
Thymocyte Deletion in 4.1-F1 Mice Is Preceded by Positive
Selection and Is Mediated by Hematopoietic Cells. Previous stud-
ies have shown that the factors underlying the MHC-linked
resistance to spontaneous IDDM predominantly reside in
the bone marrow (17, 33, 44–48). To determine whether
deletion of diabetogenic thymocytes in 4.1-F1 mice was
mediated by hematopoietic cells or by thymic epithelial
cells, we transfused bone marrow from deleting H-2g7/b– or
selecting H-2g7-4.1 mice into lethally-irradiated nontrans-
genic NOD (H-2g7) or (N 3 B) F1 mice (H-2g7/b), respec-
tively, and followed the fate of 4.1 thymocytes in the chi-
meras. As shown in Fig. 8, the mice that received marrow
from H-2g7/b–4.1 mice (expressing I-Ab only on hemato-
poietic cells), but not those that received marrow from
H-2g7-4.1 mice (expressing I-Ab only on thymic epithelial
cells), had a phenotype compatible with deletion (low thy-
mocyte CD41CD82/CD42CD82 ratios and small per-
Figure 6. Peripheral beta cell-
reactivity in I-Abb- 4.1-(N 3 B)
F1, 4.1/I-Ak-NOD, 4.1-NOD.
H-2g7/q, and 4.1-NOD.H-2g7/nb1
mice. Assays were done as in Fig.
1 C. Values correspond to cul-
tures of 2 3 104 CD41 T cells
with 5 3 104 (left) or 105 NOD
islet cells (middle and right).
Figure 7. CD4, CD8, and Vb11 profiles of thymocytes from transgenic mice homozygous for nonselecting or deleting H-2 haplotypes. See legend to
Fig. 1 for details. Data are average values corresponding to 7–10 mice/group. H-2b and H-2k 4.1 mice had fewer thymocytes (P ,0.006), and more
CD42CD82 thymocytes than H-2s 4.1 mice (P ,0.02) (Mann-Whitney U test).1071 Schmidt et al.
centages of Vb111CD41CD82 thymocytes). It thus ap-
pears that deletion of thymocytes in 4.1-F1 hybrid mice is
preceded by their positive selection on radioresistant thy-
mic epithelial cells, and is mediated by hematopoietic cells.
This finding raised one final question: if deletion is pre-
ceded by positive selection, why does it also occur in mice
homozygous for the deleting H-2 haplotypes, which lack
the selecting I-Ag7 molecule? We reasoned that the 4.1-
TCR might actually perceive the deleting I-A molecules
(i.e., I-Ab) expressed on thymic epithelial cells as selecting.
To test this hypothesis, we followed the fate of 4.1 thy-
mocytes arising from marrow of H-2g7–4.1 mice in lethally
irradiated H-2s/b mice, which express deleting (I-Ab) and
nonselecting/nondeleting (I-As), but not selecting (I-Ag7),
MHC class II molecules on thymic epithelial cells. As
shown in Fig. 8 (right), the thymocyte profiles of recipient
mice were indistinguishable from those of H-2g7/b mice
transplanted with marrow from H-2g7–4.1 mice, which
were nondeleting (Fig. 8, middle). It thus appears that in
heterozygotes, the 4.1-TCR senses the I-Ab molecules ex-
pressed by thymic epithelial cells as selecting, rather than as
deleting.
Discussion
The first striking observation of this study was the find-
ing that positive selection of the 4.1-TCR in NOD mice
caused a dramatic acceleration of the onset of IDDM (by
z3 mo). This was surprising to us considering the observa-
tions of Katz et al. in transgenic NOD mice expressing an-
other beta cell–specific and I-Ag7–restricted transgenic TCR
(BDC-2.5) (32, 41). BDC-2.5 mice do not develop an ac-
celerated onset of diabetes (32, 41) and, when housed un-
der specific pathogen-free conditions (41), develop diabetes
less frequently than 4.1-NOD mice (15 versus 74%). We
are confident that beta cell destruction in 4.1-NOD mice
was triggered and/or effected by CD41 T cells expressing
the 4.1-TCR since recombination activating gene 2–defi-
cient 4.1-NOD mice, which cannot rearrange endogenous
TCR genes, develop IDDM as early, and as frequently, as
recombination activating gene-21 4.1-NOD mice (Ver-
daguer, J., D. Schmidt, B. Anderson, A. Amrani, and P.
Santamaria, manuscript in preparation). Most surprising,
however, was the observation that 4.1 thymocytes undergo
deletion in diabetes-resistant H-2g7/b–, H-2g7/k–, H-2g7/q–,
and H-2g7/nb1–4.1-NOD mice by engaging antidiabetoge-
nic I-A (I-Ab, I-Ak, I-Aq) and, possibly, I-E molecules (I-Ek,
I-Enb1) on thymic APCs, particularly since previous studies
did not find evidence for deletion of autoreactive T cells in
congenic or transgenic NOD mice expressing these MHC
class II molecules (7, 15, 16, 32, 33, 44). This deletion was
clearly not mediated by endogenous superantigens binding
to Vb11, since it was absent in TCR-b–transgenic and
nontransgenic mice expressing the deleting MHC haplo-
Figure 8. Bone marrow chimeras. Bone marrow cells (5–10 3 106) from donor mice (4.1-NOD or 4.1-[N 3 B] F1 mice) were injected into the tail
veins of lethally irradiated recipient mice (nontransgenic NOD, [N 3 B] F1 or [B 3 S] F1 mice). Thymi of chimeric mice were analyzed by flow cytom-
etry (as in Fig. 1), 5–6 wk after transplantation. Data represent average values of 2–4 mice/group. The mice that received marrow from H-2g7/b-4.1 mice
(left) had lower thymocyte CD41CD82/CD42CD82 ratios and fewer Vb111CD41CD82 thymocytes than mice which received marrow from H-2g7-
4.1 mice (middle) (P ,0.05).1072 T Cell Tolerance versus the MHC-linked Resistance to Diabetes
types, and segregated as a single locus trait (MHC linked) in
backcross studies. Thus, the 4.1-TCR is unique in that it is
both highly diabetogenic and promiscuous.
Abrogation of I-Abb expression in TCR-transgenic I-Abb2
(N 3 B) F1 mice clearly restored the positive selection of
the 4.1-TCR; however, it did not completely eliminate its
negative selection, as suggested by the greater percentage of
CD42CD82 thymocytes in these mice versus age-matched
4.1-NOD mice. Partial deletion of transgenic thymocytes
in I-Abb- (N 3 B) F1 mice, which express the C57BL/6-
derived I-Aab gene, may be a result of engagement of
I-Abg7/I-Aab complexes by the 4.1-TCR with an affinity/
avidity approaching the threshold for deletion, or perhaps,
to other tolerogenic factors unique to the C57BL/6 back-
ground. Similarly, thymocyte deletion in H-2g7/k 4.1-F1
and -F2 mice, which express both I-Ak and I-Ek molecules,
was clearly more efficient than that observed in I-Ak–transgenic
4.1-NOD mice, raising the possibility that thymocyte dele-
tion in the former also involves the engagement of I-Ek
and/or I-Eak/I-Ebg7 molecules by the 4.1-TCR. An alter-
native, but not mutually exclusive, possibility is that the
timing and levels of I-Ak expression in I-Ak–transgenic 4.1-
NOD mice are different than the timing and levels of ex-
pression of endogenous I-Ak molecules in H-2g7/k 4.1-F1
or -F2 mice. In this respect, it is worth noting that, unlike
wild-type H-2k mice, I-Ak-transgenic NOD mice do not
express I-Ak molecules on bone marrow cells (they do,
however, express them on bone marrow–derived APCs),
and that the thymic cortical epithelial cells of I-Ak–trans-
genic NOD mice express lower levels of I-Ak than those of
H-2k mice (13). Whatever the explanation for these differ-
ences, the MHC-induced T cell tolerance in H-2g7/b and
H-2g7/k 4.1-F1 and -F2 mice was complete. Deletion of the
4.1-TCR was also observed in 4.1-NOD.H-2g7/nb1 mice
(complete deletion), which express I-Anb1 and I-Enb1 mole-
cules, and in 4.1-NOD.H-2g7/q mice (partial deletion),
which express I-Aq, but not I-E, molecules. It thus appears
that, unlike many other MHC class II–restricted TCR
specificities (32, 38, 40), the highly diabetogenic 4.1-TCR
can engage several distinct MHC class II molecules in the
thymus with totally different consequences, i.e., positive
selection or dominant negative selection.
The extensive promiscuity of the 4.1-TCR raises a series
of important questions. How can 4.1 thymocytes recognize
so many different MHC class II molecules? Does the 4.1-
TCR recognize each of these different molecules bound to
specific peptides? Or to a common peptide? Or, does it
bind to all of them regardless of the molecular nature of the
bound peptides? Is there anything unique about the molec-
ular structure of the deleting I-A molecules that makes
them function as such? We do not yet have answers to
these questions, but we have some clues. For example, we
know that the diabetogenic 4.1-TCR is not a classic allore-
active TCR; the MHC molecules that mediated deletion
of the 4.1-TCR when presented by thymic APCs did not
trigger proliferation of naive and preactivated CD41 T cells
from 4.1-NOD mice when presented by peripheral APCs
from deleting F1 backgrounds (our unpublished data). Since
thymocyte tolerance is a more sensitive response than pe-
ripheral T cell activation (43), these results need not imply
that the putative peptide–MHC class II complexes that me-
diate thymic deletion in our system are expressed solely by
a specialized thymic APC subpopulation; they may also be
present on peripheral APCs, but may not be able to trigger
mature T cell proliferation. We also know that the I-Ab
chains of all the deleting I-A molecules that we have tested
so far (I-Ab, I-Ak, and I-Aq) share residues at positions 57
(aspartic acid; Asp) and 61 (tryptophan). Interestingly, I-Ek
and I-Enb1 molecules, which are encoded on the deleting
H-2k and H-2nb1 haplotypes, respectively, have the same
residues at these two positions (49). I-Anb1, which is en-
coded on the deleting H-2nb1 haplotype (but may or may
not be engaged by the 4.1-TCR), is also Asp-571 and, like
I-Ab, I-Ak, and I-Aq, has a bulky hydrophobic residue at
position 61 (phenylalanine). We are not certain as to whether
the presence of aspartic acid at I-Eb and/or I-Ab position
57, which is negatively associated with human and murine
IDDM (1, 2), is neccessary to trigger deletion of the 4.1-
TCR. However, we know it is not sufficient, since I-As is also
Asp-571, but it is nondeleting.
Whatever the specific residues involved, the unexpected
promiscuity of the highly pathogenic 4.1-TCR raises the
intriguing possibility that pathogenicity of autoreactive
TCRs and their ability to cross-react with different MHC
class II molecules are related phenomena. At the present
time, it is difficult to envision how promiscuity may lead to
pathogenicity. It is possible, however, that promiscuous au-
toreactive TCRs, like the 4.1-TCR, are primarily selected
(positively and/or negatively) by reaction with MHC resi-
dues rather than with peptide residues, as recently proposed
for alloreactive TCRs (50). Like the latter (50), these pro-
miscuous autoreactive TCRs may then be able to engage a
larger range of peripheral self-peptide–selecting MHC
complexes above the affinity threshold required for mature
T cell activation than nonpromiscuous autoreactive TCRs,
resulting in increased chances for pathogenicity. This
would predict that promiscuity would not be unusual
among those autoreactive TCRs with the highest patho-
genic potential (i.e., those that trigger diabetes), and that
MHC molecules providing dominant resistance to a given
autoimmune disease would do so predominantly by re-
moving the most pathogenic autoreactive T cells rather
than all autoreactive T cells, regardless of their pathogenic-
ity (i.e., those recruited during amplification of the autoim-
mune response). This postulate would provide an explana-
tion as to why the beta cell–reactive and I-Ag7–restricted
BDC-2.5-TCR of Katz et al. (32), which does not acceler-
ate IDDM onset in NOD mice (32, 41), did not undergo
tolerance in H-2g7/b F1 mice or in I-E–trangenic NOD
mice (32). It would also account for the presence of mildly
insulitogenic, but not diabetogenic, T cells in some con-
genic NOD.H-2g7/b, NOD.H-2g7/q, or NOD.H-2g7/nb1 mice
(7, 15, 16), I-Ad–transgenic NOD mice (18), NOD mice
reconstituted with bone marrow from I-Ea–transgenic
NOD mice (33), and I-Ak-transgenic NOD mice (12, 13).
In evaluating the relevance of our findings in 4.1 mice1073 Schmidt et al.
with respect to the MHC-linked susceptibility and resis-
tance to spontaneous IDDM in non-TCR–transgenic
mice, one should consider two additional aspects. The first
aspect has to do with the pathophysiological consequences
of thymocyte selection in 4.1 mice. There was an absolute
correlation between deletion of thymocytes in H-2g7/b and
H-2g7/k 4.1-F2 mice and resistance to insulitis and diabetes;
deleting offspring of the second backcross of 4.1-F1 mice
to NOD mice never developed insulitis, whereas all their
nondeleting littermates developed moderate to severe insu-
litis, and z50% of those which inherited two H-2g7 haplo-
types became diabetic (a significant percentage given the
polygenic nature of murine IDDM; reference 2). The same
was true for 4.1-NOD.H-2g7/q and 4.1-NOD.H-2g7/nb1
mice, which developed mild periinsulitis or no insulitis, re-
spectively, and did not become diabetic. It is noteworthy
that these observations are highly reminiscent of the resis-
tance of NOD.H-2g7/b, NOD.H-2g7/q, or NOD.H-2g7/nb1-
congenic mice, and of I-E–, I-Ad–, and I-Ak–transgenic
NOD mice to insulitis and/or IDDM (6–14, 16–18). The
second aspect relates to the geography and timing of nega-
tive selection of diabetogenic thymocytes in 4.1 mice. As in
other models of thymocyte selection (51, 52), negative se-
lection of thymocytes in 4.1-F1 mice was preceded by pos-
itive selection and was mediated by hematopoietic cells.
This observation also accords with the widely accepted no-
tion that the factors underlying the MHC-linked resistance
to spontaneous IDDM predominantly reside in the bone
marrow (17, 33, 44–48). Taken together, then, these data
lend strong support to the hypothesis that the MHC-asso-
ciated resistance to insulitis and IDDM of non-TCR–trans-
genic mice (and perhaps humans) may also result from neg-
ative selection of highly diabetogenic thymocytes.
Nonetheless, deletion of diabetogenic thymocytes does
not account for all the protection afforded by MHC class II
molecules. It appears, also, that in the absence of additional
susceptibility factors and/or in the presence of additional
resistance factors, positive selection of autoreactive T cells
bearing pathogenic TCRs does not automatically imply au-
toreactivity. These interpretations stem from three observa-
tions. First, I-Ak/4.1-NOD mice developed insulitis but
not diabetes, suggesting that engagement of the partially
deleting I-Ak molecules by the few 4.1 T cells that escaped
deletion/anergy might have fostered their differentiation
into nondiabetogenic Th-cells (perhaps of the Th2 type, or
of the Th1 type, but incapable of effecting beta cell dam-
age). Second, unlike their H-2g7 littermates, the H-2g7/k
4.1-F2 mice that did not tolerate the 4.1-TCR (40%) only
developed nondiabetogenic insulitis. The reasons behind
the diabetes resistance of these mice may be similar to those
argued above for I-Ak/4.1-NOD mice. Alternatively, pro-
gression from moderate to severe insulitis and overt diabe-
tes may require a double dose of the beta cell antigen–I-Ag7
complex(es) targeted by diabetogenic T cells, as proposed
in nontransgenic systems (16). Finally, I-Abb–deficient 4.1-
(N 3 B) F1 mice developed insulitis but remained diabe-
tes-resistant, and 4.1-(N 3 S) F1 mice, which also ex-
ported functional 4.1 T cells to the periphery, developed
neither diabetes nor insulitis. Whether the diabetes resis-
tance of these mice is due to I-Ag7 hemizygosity, to the
presence of additional C57BL/6- or SJL-derived resistance
elements, or to “dilution” of NOD-derived recessive sus-
ceptibility factors, is currently under investigation.
Whatever the nature and function of these additional
protective elements turn out to be, our observations in 4.1-
TCR–transgenic mice have unearthed what, at the outset
of this study, seemed to be an unlikely proposition, namely,
the existence of a relationship between thymocyte selection
of highly pathogenic T cells and the MHC-linked suscepti-
bility and resistance to one spontaneous autoimmune dis-
ease, IDDM. Our results do not imply that deletion is the
only mechanism for autoimmune disease protection af-
forded by MHC class II molecules, but explain how pro-
tective MHC genes carried on one haplotype (e.g., I-Ab in
mice and DQA1*0102/DQB1*0602 in humans) can over-
ride the genetic susceptibility provided by MHC genes car-
ried on a second haplotype (e.g., I-Ag7 in mice and
DQA1*0301/DQB1*0302 in humans).
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